Seven Oral Presentations: Innovent to Present Breakthrough Clinical Data of IBI363?PD-1/IL-2?-bias?and Other Novel Drug Candidates at the 2025 ASCO Annual Meeting | IVBIY Stock News

Author's Avatar
Apr 23, 2025
  • Innovent Biologics (IVBIY, Financial) to present seven oral presentations at the 2025 ASCO Annual Meeting in Chicago.
  • Key presentations include IBI363 for melanoma, colorectal cancer, and non-small cell lung cancer.
  • Phase 1b data for IBI343 in pancreatic cancer will also be presented, highlighting significant potential.

Innovent Biologics (IVBIY), a leader in innovative biopharmaceuticals, will showcase breakthrough clinical data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, happening from May 30 to June 3, in Chicago, Illinois. The company is set to deliver seven oral presentations highlighting major developments in its oncology pipeline.

Among the key presentations, IBI363, a first-in-class PD-1/IL-2?-bias bispecific antibody, will feature in presentations covering three critical indications: melanoma, colorectal cancer (CRC), and non-small cell lung cancer (NSCLC). These presentations underscore IBI363's role in advancing PD-1-based immunotherapy.

Moreover, IBI343, a CLDN18.2 ADC, will be presented with Phase 1b data in pancreatic cancer. This follows a successful presentation at ESMO Asia and further emphasizes its potential in the challenging therapeutic area of pancreatic cancer.

Innovent's robust presence in both Immuno-oncology (IO) and Antibody-Drug Conjugates (ADC) platforms will be further solidified through additional presentations, including the ORIENT-21 Phase 3 study of sintilimab plus ICE in Hodgkin lymphoma, the SPRING-01 trial in rectal cancer, and the EP-STAR trial in nasopharyngeal carcinoma.

Dr. Hui Zhou, Senior Vice President of Innovent, expressed confidence in the advancing pivotal-stage development of these innovative candidates, aiming to address global unmet clinical needs with effective, safe treatment options.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.